The content on this site is intended for healthcare professionals only
Prof Bruno Sangro speaks to ecancer in an online interview for the virtual ESMO GI 2020 meeting.
He describes the background and design of this phase III trial, which looked at the long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (aHCC).
Prof Sangro reports that what the survival curves show is that they start separating at month 8, leading to a higher overall survival rate for nivolumab versus sorafenib at both 12 months and 24 months.
He reveals that, at 33.6 months, the survival rate for nivolumab was 29% and 21% for sorafenib.
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
ASCO 2024: Lung cancer highlights
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
ASCO 2024: Lung cancer roundup
Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma
